gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 24 Oct 2014.

V-raf murine sarcoma viral oncogene homolog B1

BRAF
This gene encodes a protein belonging to the raf/mil family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene are associated with cardiofaciocutaneous syndrome, a disease characterized by heart defects, mental retardation and a distinctive facial appearance. Mutations in this gene have also been associated with various cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, non-small cell lung carcinoma, and adenocarcinoma of lung. A pseudogene, which is located on chromosome X, has been identified for this gene. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: KRAS, Raf, CAN, HAD, EGFR
Papers using BRAF antibodies
Induction of autophagy and inhibition of melanoma growth in vitro and in vivo by hyperactivation of oncogenic BRAF
Supplier
Pal Soumitro, In PLoS ONE, 2009
... All primary antibodies were purchased from Cell Signaling Technology except the following: anti-BRAF from Santa Cruz Biotechnology, anti-CRAF from BD Biosciences, ...
RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults
Supplier
LiVolsi Virginia A et al., In CytoJournal, 2000
... The amplified products were electrophoresed on a 1.2% gel at 110 V for 1.5 hours and the BRAF bands (~220 bp) were cut using sterile blade and purified using Qiagen Gel Extraction Kit (Hilden, ...
A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)
Supplier
Brinker Achim et al., In Current Chemical Genomics, 1993
... Unconjugated B-Raf antibody was from Santa Cruz Biotechnology (sc-5284), pMEK1/2 antibody from ...
Papers on BRAF
Medullary carcinoma of the colon: can the undifferentiated be differentiated?
New
Willemoe et al., Copenhagen, Denmark. In Virchows Arch, 23 Nov 2014
An extensive immunohistochemical panel was performed, and KRAS, NRAS, and BRAF mutational status was assessed.
Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma.
New
Smalley et al., Tampa, United States. In Proteomics, 22 Nov 2014
The unification of genotype-specific cell line data revealed the enrichment for the tyrosine-phosphorylated cytoskeletal proteins to be associated with the presence of a BRAF mutation and oncogenic NRAS to be associated with increased receptor tyrosine kinase phosphorylation.
Phenotype Switching: Tumor Cell Plasticity as a Resistance Mechanism and Target for Therapy.
Review
New
van Amerongen et al., Amsterdam, Netherlands. In Cancer Res, 15 Nov 2014
UNLABELLED: Mutations in BRAF are present in the majority of patients with melanoma, rendering these tumors sensitive to targeted therapy with BRAF and MEK inhibitors.
Review of the current targeted therapies for non-small-cell lung cancer.
Review
New
Wakelee et al., Stanford, United States. In World J Clin Oncol, 10 Nov 2014
Emerging therapies directed against other driver oncogenes in NSCLC including ROS1, HER2, and BRAF are covered as well.
Recent Therapeutic Advances in the Treatment of Colorectal Cancer.
New
Goldberg et al., Columbus, United States. In Annu Rev Med, 09 Nov 2014
Molecular profiling of metastatic colorectal cancer (including mutational analysis for KRAS, NRAS, BRAF, PIK3CA, and others) has become increasingly important for identification of prognostic and predictive biomarkers, as well as for insights into the biology that drives the tumor.
Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAFV600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor.
New
Impact
Gonzalez et al., Nashville, United States. In J Clin Oncol, 06 Nov 2014
PURPOSE: Preclinical and early clinical studies have demonstrated that initial therapy with combined BRAF and MEK inhibition is more effective in BRAF(V600)-mutant melanoma than single-agent BRAF inhibitors.
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma.
New
Impact
Ribas et al., Bergamo, Italy. In N Engl J Med, 29 Oct 2014
UNLABELLED: Background The combined inhibition of BRAF and MEK is hypothesized to improve clinical outcomes in patients with melanoma by preventing or delaying the onset of resistance observed with BRAF inhibitors alone.
Nrf2, the master redox switch: The Achilles' heel of ovarian cancer?
Review
New
Rots et al., Groningen, Netherlands. In Biochim Biophys Acta, 27 Oct 2014
Particularly, we propose to stratify patients based on common ovarian cancer mutations (KRAS, BRAF, ERBB2, BRCA1 and its link with estradiol, TP53) for future NRF2 targeting strategies.
Novel Approaches in Anaplastic Thyroid Cancer Therapy.
Review
New
Chen et al., Madison, United States. In Oncologist, 26 Oct 2014
This review will cover several cellular signaling pathways and mechanisms, including RET/PTC, RAS, BRAF, Notch, p53, and histone deacetylase, which are identified to play roles in the transformation and dedifferentiation process, and therapies that target these pathways.
Structure of the BRAF-MEK Complex Reveals a Kinase Activity Independent Role for BRAF in MAPK Signaling.
New
Impact
Malek et al., San Francisco, United States. In Cancer Cell, 08 Oct 2014
Numerous oncogenic mutations occur within the BRAF kinase domain (BRAF(KD)).
eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies.
New
Impact
Vagner et al., Villejuif, France. In Nature, 04 Oct 2014
In BRAF(V600)-mutant tumours, most mechanisms of resistance to drugs that target the BRAF and/or MEK kinases rely on reactivation of the RAS-RAF-MEK-ERK mitogen-activated protein kinase (MAPK) signal transduction pathway, on activation of the alternative, PI(3)K-AKT-mTOR, pathway (which is ERK independent) or on modulation of the caspase-dependent apoptotic cascade.
Molecular pathogenesis and targeted therapies in well-differentiated thyroid carcinoma.
Review
New
Kim, Taegu, South Korea. In Endocrinol Metab (seoul), 30 Sep 2014
Four proto-oncogenes commonly associated with well-differentiated thyroid carcinoma, rearranged during transfection (RET)/papillary thyroid cancer, BRAF, RAS, and PAX8/peroxisome proliferator activated receptor-╬│, may carry diagnostic and prognostic significance.
Clinical and Molecular Findings of Tunisian Patients with RASopathies.
New
Rebai et al., Sfax, Tunisia. In Mol Syndromol, Aug 2014
Mutations in PTPN11 and SOS1 genes were found in patients with diagnosis of NS and BRAF gene mutations in patients with CFC syndrome.
Systemic treatment for BRAF-mutant melanoma: where do we go next?
New
Impact
Long et al., Sydney, Australia. In Lancet Oncol, Aug 2014
After decades of treatment failure for metastatic melanoma, the development of BRAF inhibitors was highly anticipated to dramatically improve outcomes for patients with oncogene-addicted BRAF-mutant metastatic melanoma.
Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
New
Poetsch et al., Kristiansand, Norway. In Int J Clin Exp Pathol, Dec 2013
To evaluate the suitability of colorectal cancer (CRC) tissue for these treatment approaches and to find a possible link to pretherapeutic conditions of other targeted strategies, we compared neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutational status in primary and metastatic CRC.
The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway.
GeneRIF
Pritchard et al., Leicester, United Kingdom. In Genes Dev, 2012
endogenous expression of (L597V)Braf leads to approximately twofold elevated Braf kinase activity and weak activation of the Mek/Erk pathway
BRAF duplications and MAPK pathway activation are frequent in gliomas of the optic nerve proper.
GeneRIF
Eberhart et al., Baltimore, United States. In J Neuropathol Exp Neurol, 2012
The results of this study supported an important role for BRAF duplication and MAPK pathway activation in gliomas of the optic nerve proper.
BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis.
Review
GeneRIF
Xing et al., Baltimore, United States. In Medicine (baltimore), 2012
Thus, in this meta-analysis, the BRAF mutation in PTC was significantly associated with PTC recurrence, lymph node metastasis, extrathyroidal extension, and advanced stage AJCC III/IV.
KRAS and BRAF mutations in Serbian patients with colorectal cancer.
GeneRIF
Jankovic et al., Belgrade, Serbia. In J Buon, 2012
the spectrum and frequency distribution of the identified KRAS and BRAF mutations in Serbian patient with colorectal cancer are in good accordance with literature data.
A cardio-facio-cutaneous syndrome case with tight Achilles tendons.
GeneRIF
Ozkinay et al., ─░zmir, Turkey. In Genet Couns, 2011
Cardio-facio-cutaneous syndrome is caused by heterogeneous mutations in BRAF gene.
share on facebooktweetadd +1mail to friends